

A case of AML characterized by a novel t(4;15)(q31;q22) translocation that confers a growth-stimulatory response to retinoid-based therapy

Brown, Geoffrey

License:

Creative Commons: Attribution (CC BY)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Brown, G 2017, 'A case of AML characterized by a novel t(4;15)(q31;q22) translocation that confers a growth-stimulatory response to retinoid-based therapy', *International Journal of Molecular Sciences*.

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 06/07/2017

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

A case of AML characterized by a novel t(4;15)(q31;q22) translocation that confers a growth-stimulatory response to retinoid-based therapy

Justin M. Watts^{1,†}, Aymee Perez^{1,†}, Luteicia Pereira¹, Yao-Shan Fan², Geoffrey Brown^{3,4}, Francisco Vega², Kevin Petrie^{5,*}, Ronan T. Swords¹, Arthur Zelent^{1,*}.

¹ Division of Hematology/Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL33136, USA.

² Department of Pathology, Miller School of Medicine, University of Miami, Miami, FL33136, USA.

³ Institute of Immunology and Immunotherapy, ⁴ Institute of Clinical Sciences, University of Birmingham, Birmingham, B15 2TT, UK.

⁵ Faculty of Natural Sciences, University of Stirling, Stirling, FK9 4LA, UK.

[†] These authors contributed equally to this study.

* Correspondence: kevin.petrie@stir.ac.uk; Tel.: +44-991786-466840. a.zelent@med.miami.edu; Tel.: +1-305-243-5071.

Abstract: Here, we report the case of a 30-year old woman with relapsed AML who was treated with all-*trans* retinoic acid (ATRA) as part of investigational therapy (NCT02273102). The patient died from rapid disease progression following eight days of continuous treatment with ATRA. Karyotype analysis and RNA-Seq revealed the presence of a novel t(4;15)(q31;q22) reciprocal translocation involving the *TMEM154* and *RASGRF1* genes. Analysis of primary cells from the patient revealed expression of *TMEM154-RASGRF1* mRNA and the resulting fusion protein but no expression of the reciprocal *RASGRF1-TMEM154* fusion. Consistent with the response of the patient to ATRA therapy, we observed a rapid proliferation of t(4;15) primary cells following ATRA treatment *in vitro*. Preliminary characterisation of the retinoid response of t(4;15) AML revealed that, in stark contrast to non-t(4;15) AML, these cells proliferate in response to specific agonists of RAR α and RAR γ . Furthermore, we observed an increase in the levels of nuclear RAR γ upon ATRA treatment. In summary, the identification of the novel t(4;15)(q31;q22) reciprocal translocation opens new avenues in the study of retinoid resistance and provides potential a new biomarker for therapy of AML.

1. Introduction

Acute myeloid leukemia (AML) is the most commonly occurring leukemia in adults, accounting for an estimated 33% of all cases and more than 80% of acute cases in 2016 [1]. AML is a disease whose incidence increases with age and, in line with an aging population, this has increased from 3.4 per 100,000 in 2004 to 5.1 per 100,000 in 2013 [2]. Advances in the treatment of AML have dramatically improved treatment outcomes for younger patients with a relative 5-year survival rate (2005-2011) of approximately 67% (0-14 years) [1]. In the elderly, however, who account for the majority of new cases, the prognosis remains poor. Indeed, AML accounts for an estimated 43% of all leukemia deaths, with an overall average 5-year survival rate of only 27% [2].

The use of combination therapy based on the use of all-trans retinoic acid (ATRA) and arsenic trioxide (As_2O_3) has revolutionized the clinical outcome of acute promyelocytic leukemia (APL), with complete remission rates of 90% and cure rates of around 80% [3]. The success of ATRA-based therapy in AML has, however, not been translated into other non-APL subtypes of AML. Based on *in vitro* data showing efficacy with cytotoxic chemotherapy agents, such as Ara-C and anthracyclines, several clinical studies have investigated the impact of adding ATRA to chemotherapy in patients with non-APL AML [4]. Unfortunately, however, these studies have yielded inconsistent and conflicting results. One possible reason for a lack of response to ATRA treatment in non-APL AML patients is epigenetic repression of the retinoic acid receptor pathway, especially the *RARA* gene [5]. Indeed, combination therapy of ATRA with epi-drugs targeting the histone H3 lysine 4 demethylase LSD1 (KDM1A) has shown promise in *in vivo* models of AML [6]. This approach is now being evaluated in a phase I clinical trial where patients are given escalating doses of the LSD1 inhibitor Parnate (tranylcypromine, TCP) with fixed continuous doses of ATRA.

Acute myeloid leukemia (AML) is characterized by clonal or oligoclonal hematopoiesis that varies amongst patients. On average, at least 4-5 oncogenic mutations or chromosomal abnormalities are present at diagnosis, along with passenger mutations of unclear significance [7]. Clonal evolution occurs after exposure to chemotherapy and the secondary mutations that give rise to these clones are

more likely to be random, as opposed to recurrent primary abnormalities [8]. We report here a case of relapsed AML characterised by a previously unidentified chromosomal translocation.

2. Results

2.1 Clinical presentation

A 30-year-old, previously healthy African-American female, presented with a white blood cell count (WBC) of 180,000/ μ l, haemoglobin 7.6 g/dl, platelets 93,000/ μ l. Physical examination was unremarkable. Bone marrow aspiration and biopsy were consistent with AML with monocytic differentiation. Blasts amounted to 95% of nucleated elements and expressed CD34, CD117, CD13, CD33, CD64 (weak), CD38, HLA-DR and were negative for TdT and MPO by flow cytometry. Cytogenetic analysis revealed an abnormal female karyotype: 46,XX,t(9;11)(p22;q23)[13]/46,XX[7]. Additionally, mutational analysis revealed an activating mutation in *NRAS* gene (c.34G>A; p.G12S). Following treatment with standard therapy, the patient achieved complete cytogenetic remission. Post remission therapy followed, with sequential cycles of high dose cytarabine in the absence of an optimal donor. Following a disease-free interval of 8 months, the patient relapsed. Karyotype at relapse was consistent with clonal evolution: 46,XX,t(4;15)(q31;q22), t(9;11)(p22;q23)[20] (**Figure 1A**). Mutational analysis confirmed the presence of an *NRAS* mutation as before. The patient failed 2 lines of salvage chemotherapy. In the setting of chemotherapy refractory disease, the patient was enrolled on the phase I clinical trial (NCT02273102) and given escalating doses of TCP with fixed continuous doses of ATRA. However, the patient died from rapid disease progression after eight days of treatment (WBC at screening was 400/ μ l and at withdrawal from study WBC was 99,300/ μ l).

2.2 Molecular and functional characterization of the t(4;15) fusion gene

To characterize the translocation partners and their breakpoints, we used RNA-Seq and Sanger sequencing, confirming the t(9;11) *MLL(KMT2A)*-*AF9(MLLT3)* reciprocal translocation present at diagnosis (data not shown). We also defined a novel fusion gene comprising exons 1-6 of the *TMEM154* gene (4q31.3) and exons 15-24 of the *RASGRF1* gene (15q24.2) (**Figure 1B**). This generates a putative 830 amino acid TMEM154-RASGRF1 fusion protein comprising amino acids 1-

178 of TMEM154 and 622-1273 of RASGRF1 (**Figure 1C**). RT-PCR analysis confirmed the presence of TMEM154-RASGRF1 mRNA in t(4;15) AML cells but not normal controls (**Figure 1D, lanes 1-2 and 5-6**). By contrast, controls for TMEM154 were present in both t(4;15) AML cells and normal controls (**Figure 1D, lanes 4 and 8**). Consistent with the RNA-Seq results, expression of mRNA transcripts arising from the reciprocal *RASGRF1-TMEM154* fusion gene were not detected in t(4;15) AML cells (**Figure 1D, lane 3**).




Figure 1. Analysis of the t(4;15)(q31;q22) reciprocal chromosomal translocation. **(A)** Conventional karyotyping showing 46,XX, t(4;15)(q31;q22), outlined in red and t(9;11)(p22;q23), outlined in blue. Chromosome analysis was performed on 20 G-banded metaphase cells from multiple unstimulated cultures. Both translocations were present in all cells examined. **(B)** Breakpoint analysis of the novel fusion transcript produced by the t(4;15) chromosomal translocation. *TMEM154* and *RASGRF1* form a chimeric mRNA transcript with breakpoints as indicated. **(C)** Sanger sequencing chromatogram showing the transcribed sequence surrounding the breakpoint. **(D)** PCR analysis of *TMEM154-RASGRF1*, *RASGRF1-TMEM154* and *TMEM154* transcripts. PCR was performed on t(4;15) AML cells (lanes 1-4) and bone marrow mononuclear cells (BM-MNC) from a healthy donor (lanes 5-8). Bands correspond to a 445 bp product amplified from *TMEM154-RASGRF1* mRNA (lanes 1 and 5), a 589 bp product amplified from *TMEM154-RASGRF1* mRNA (lanes 1 and 5) and a 445 bp product amplified from *TMEM154* mRNA (lanes 4 and 8). No product was amplified using primers corresponding to *RASGRF1-TMEM154* mRNA (lanes 3 and 7).




Figure 2. Characterization of t(4;15) AML primary cells. **(A)** Immunoblot analysis of *TMEM154-RASGRF1* expression. After 72 hours treatment, vehicle control non-t(4;15) AML cells (lane 1), vehicle control t(4;15) AML cells (lane 2) and ATRA t(4;15) AML cells (lane 3) were subjected to immunoblot analysis. Samples were probed with rabbit monoclonal antibody against a C-terminal region of RASGRF1 and mouse monoclonal antibody against a N-terminal region of TMEM154. β-actin was used as a loading control. Molecular weight standards (left) and the identities of bands (right) are indicated. **(B)** Proliferation of t(4;15) AML cells in response to retinoids. Cells were treated with vehicle control, ATRA, RARα agonist (AM-80 or AGN-195183), or RARγ agonist (AGN-205327). Cells were also treated with RARα antagonist (AGN-196996), RARγ antagonist (AGN-205728) or RARα/β/γ antagonist (AGN-194310). All retinoids were used at a concentration of 1 μM. Cell proliferation was determined by CellTiter-Glo luminescent cell viability assay (Promega) after 72 hours of treatment. Values shown are normalized to vehicle control. **(C)** Proliferation of t(4;15) and non-t(4;15) AML cells in response to retinoid agonists. Samples from t(4;15) and 7 non-t(4;15) AML patients were incubated with vehicle control, ATRA, RARα agonist (AGN-195183), or RARγ agonist (AGN-205327) at a concentration of 1 μM. Cells were analysed and normalized as described for **(B)**. **(D)** Treatment of t(4;15) cells with ATRA increases levels of nuclear RARγ. t(4;15) cells were treated with vehicle control or 1 μM ATRA and incubated for 72 hours before staining with RARα mouse monoclonal and RARγ rabbit polyclonal antibodies.

In agreement with our analysis of mRNA expression, Western blot analysis revealed expression of endogenous TMEM154 and RASGRF1 proteins, as well as TMEM154-RASGRF1 fusion protein, which could be detected using antibodies directed against both a N-terminal region of TMEM154 as well as a c-terminal region of RASGRF1 (**Figure 2A**). Interestingly, treatment with ATRA led to an increase in expression of TMEM154-RASGRF1 fusion protein but not endogenous TMEM154 or RASGRF1(**Figure 2A**). Supporting the clinical history, we observed a rapid proliferation of the patient's blasts following treatment with ATRA *in vitro* (**Figure 2B**). The same phenotype was seen when the cells were exposed to other agonists of the retinoic acid pathway. Primary cells lacking a t(4;15)(q31;q22) rearrangement displayed no growth alteration compared to controls when treated with either ATRA (a pan-RAR isotype agonist) or isotype selective agonists specific for RAR α or RAR γ (**Figure 2C**). To further examine the effects of ATRA on primary t(4;15) AML cells, we performed immunofluorescence analysis of RAR α or RAR γ . Here, we found that treatment of t(4;15) AML cells with ATRA led to an increase in nuclear RAR γ (**Figure 2D**).

3. Discussion

Our data suggest that the t(4;15)(q31;q22) reciprocal translocation confers a growth-stimulatory response to retinoid-based therapy. The basis for this response requires further investigation but could lie, at least in part, to an increase in nuclear RAR γ following ATRA treatment. While RAR α is required for myeloid differentiation, RAR γ has been shown to promote hematopoietic stem and progenitor cell self-renewal and proliferation [9]. Additionally, it is likely that the ATRA-mediated increase in TMEM154-RASGRF1 fusion protein (which is consistent with established ATRA regulation of TMEM154 [14]) cooperates with mutant NRAS G12S (which results in decreased GTPase activity and constitutive RAS signalling). Between 12-19% of AML patients possess gain-of-function mutated RAS genes [7], with NRAS being most frequently affected [10]. Furthermore, other components of the RAS pathway signalling cascade are often mutated [11]. RASGRF1 (RAS protein specific nucleotide releasing factor 1) is a guanine nucleotide exchange factor (GEF) similar to the *Saccharomyces cerevisiae* CDC25 gene product and functions to activate RAS by catalyzing the

exchange of RAS-bound GDP for GTP [12]. While we have not yet investigated the activity of TMEM154-RASGRF1 towards NRAS, it is noteworthy that the fusion protein (which lacks regulatory domains contained in N-terminal RASGRF1) contains the membrane anchoring domain of TMEM154 and functional domains of RASGRF1. These include the GDP/GTP RAS exchanger and CDC25H motifs of RASGRF1, which have been shown to be sufficient for functional protein [13].

Another aspect of the consequences of the t(4;15) translocation that merits further consideration is the fact that *RASGRF1* is a paternally expressed imprinted gene. Thus, under normal conditions only the paternal allele of the gene is translated into protein. In t(4;15) AML both the TMEM154-RASGRF1 fusion protein as well endogenous RASGRF1 are expressed, leading to possible gene dosage effects. Conversely, the lack of expression of the reciprocal *RASGRF1-TMEM154* indicates that the differentially methylated domain (DMD) located 30 kb 5' of the *RASGRF1* transcription initiating site [15] is intact, resulting in imprinted methylation. A functionally important consequence of this could be inappropriate silencing of genes downstream of *TMEM154*. Here, it is noteworthy that the gene immediately downstream of *TMEM154* is *FBXW7*, which encodes an F-box family protein that is a component of the SCF (SKP1-cullin-F-box) ubiquitin protein ligase complex. In the context of AML, *FBXW7* has clinically relevant targets including MYC, MCL-1 and Cyclin E [16, 17].

4. Materials and Methods

4.1 Patient Samples

Primary AML samples were collected by the Tissue Banking Core Facility (TBCF) at the University of Miami according to an institutional review board (IRB) approved protocol (20060858). In order to purify the mononuclear fraction, bone marrow aspirates were subjected to density gradient centrifugation using Ficoll Paque Plus (GE Healthcare Life Sciences).

4.2 DNA/RNA isolation

DNA and RNA were isolated from mononuclear cells from patient's bone marrow aspirate. DNA was isolated using QIAamp DNA Mini Kit (Qiagen) according to manufacturer's instructions. RNA

was extracted with PureLink RNA kit (Life Technologies) following manufacturer's recommendations.

4.3 RNA Seq for Breakpoint identification

Preparation of RNA libraries for sequencing on the Illumina HiSeq2500 platform was carried out in the John P. Hussman Institute for Human Genomics Center for Genome Technology at the University of Miami. Briefly, total RNA was quantified and qualified by Agilent Bioanalyzer to have an RNA integrity score (RIN) of 7. For each of the two samples, 1000ng of total RNA was used as input for the Illumina TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero to create ribosomal RNA depleted sequencing libraries. Each sample was barcoded to allow for multiplexing and was sequencing to ~30 million raw reads in a 2x125 paired end sequencing run on an Illumina HiSeq2500. Raw sequence data from the Illumina HiSeq2500 was processed by the on-instrument Real Time Analysis software (v.1.8) to basecall files. These were converted to demultiplexed FASTQ files with the Illumina supplied scripts in the BCL2FASTQ software (v1.8.4). The quality of the reads was determined with FastQC software for per base sequence quality, duplication rates, and overrepresented kmers (www.bioinformatics.babraham.ac.uk/projects/fastqc/). Illumina adapters were trimmed from the ends of the reads using Trim Galore! resulting in two trimmed FASTQ files per sample (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Reads were aligned to the human reference genome (hg19) with the STAR aligner (v2.5.0a) [18]. Gene fusions were detected in the aligned BAM files using the Manta software [19].

4.4 Accession Numbers

The Genbank accession number for *TMEM154-RASGRF1* mRNA is MF175878. RNA-Seq FASTQ files were submitted to the sequence read archive (SRA) with the Genbank accession number SRR5681084.

4.5 RT-PCR

Reverse transcription and PCR amplification was performed using One-Step RT-PCR System (Life Technologies) according to manufacturer's instructions. Primers used to amplify *TMEM154-RASGRF1* mRNA were *TMEM154*-Fwd333: 5'-TAGCCAAGGATCTCAGAGTG-3'; and *RASGRF1*-Rev778: 5'-GAATGGCACTGATAGGCTTC-3' or *RASGRF1*-Rev922: 5'-GTGACGATGTCTTGGTGATG-3'. Primers used to amplify *TMEM154* were *TMEM154*-Fwd1762: 5'-TAGCCAAGGATCTCAGAGTG-3' and *TMEM154*-Rev2272: 5'-TGAGCGCCATTCAGGTTTAG-3'. Primers to amplify *RASGRF1-TMEM154* were *RASGRF1*-Fwd1762: 5'-CTCATTTCAGGTGCCCATGTC-3' and *TMEM154*-Rev2272: 5'-TGAGCGCCATTCAGGTTTAG-3'. Amplified PCR fragments were subjected to DNA sequence (Eurofins) to validate the translocation breakpoint.

4.6 Western blot

Protein sample concentrations were normalized using DC Protein Assay (Bio-Rad). 50 µg of protein were separated by SDS-PAGE using 4–20% Mini-PROTEAN TGX pre-cast gels with Precision Plus ProteinDual Color Standards (Bio-Rad). Primary antibodies used were as follows: rabbit monoclonal antibody against the C-terminal region of *RASGRF1* (Abcam, ab118830) and mouse monoclonal antibody against the N-terminal region of *TMEM154* (Santa Cruz Biotechnology, sc-398802). β-actin was used as a loading control (Sigma, A5441). Protein bands were detected using HRP-linked Anti-rabbit IgG (Cell Signaling Technology, #7074) and HRP-linked Anti-mouse IgG (Cell Signaling Technology, #7076) secondary antibodies.

4.7 Cell proliferation

Cell proliferation was measured using CellTiter-Glow luminescent cell viability assay (Promega) following the manufacturer's recommendations. Primary AML mononuclear cells were seeded at a density of 10,000 cells/well in a 96-well plate for 24 hours, followed by retinoid or vehicle (DMSO) treatment for 72 hours. Cells were cultured in RPMI supplemented with 5% Charcoal-dextran FBS (Life Technologies). ATRA was purchased from Sigma. AM-80 was purchased from Tocris Bioscience. AGN195183, AGN196996, AGN205327, AGN205728 and AGN194310 were

manufactured under contract at the Chinese National Center for Drug Screening, Shanghai Institute of Materia Medica, Shanghai, China.

4.8 Immunofluorescence

AML cells were fixed with 4% paraformaldehyde in 1X PBS for 20 minutes at room temperature. For immunostaining, cells were permeabilized with 1% Triton X-100 in 1XPBS and blocked with 2.5% BSA and 1% Triton X-100 in 1X PBS for 1 hour shaking at room temperature. Primary antibodies (dilution 1:100) were incubated for 2 hours at room temperature in blocking buffer and washed 5 times with wash buffer (0.1% Triton X-100 in 1X PBS). Primary antibodies used were RAR α -9a (mouse monoclonal) and RAR γ -453 (rabbit polyclonal) (gift from Dr. Cécile Rochette-Egly, L'Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), France). Secondary antibodies (dilution 1:1000) were added for 1 hour at room temperature in blocking buffer and then washed 5 times. Secondary antibodies used were Alexa Fluor 488-conjugated anti-mouse IgG (H+L), F(ab')₂ fragment (Cell Signaling Technology, #4408) and Alexa Fluor 555-conjugated anti-rabbit IgG (H+L), F(ab')₂ fragment (Cell Signaling Technology, #4413). Slides were then mounted with ProLong Gold antifade reagent with DAPI (Molecular Probes), following the manufacturer instructions. Immunofluorescence microscopy was performed using a Leica DFC 310 FX microscope.

5. Conclusions

We report here a case of relapsed AML characterised by a novel translocation associated with aggressive disease and increased proliferation in the presence of ATRA. We are currently generating a cell line bearing this translocation that will provide a new model system for the study of AML. Although the *TMEM154-RASGRF1* translocation is likely to be a rare occurrence, as has been the case in the past with other translocations, it is predicted that further study of its biology will yield important insights into retinoic acid signalling and resistance to retinoid-based therapy in AML.

Acknowledgments: This study was supported by Grant Number KL2TR000461, Miami Clinical and Translational Science Institute, from the National Center for Advancing Translational Sciences and

the National Institute on Minority Health and Health Disparities. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Author Contributions: Justin M. Watts, Aymee Perez, Ronan T. Swords and Arthur Zelent conceived and designed the study. Justin M. Watts collected the clinical data. Aymee Perez, Omar Lopez, Ana Rodrigues and Lutezia Pereira performed laboratory experiments. Yao-Shan Fan performed cytogenetic analysis. Justin M. Watts, Aymee Perez and Kevin Petrie analyzed and interpreted data and wrote the manuscript. Terrence Bradley, Fernando Vargas, Sandra Algaze, Omar Lopez, Ana Rodrigues, Lutezia Pereira, Yao-Shan Fan, Veronica Gil, Geoffrey Brown, Jennifer Chapman, Francisco Vega Ronan T. Swords and AZ analyzed and interpreted data, and edited the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer statistics, 2016. *CA Cancer J Clin* **2016**, 66, (1), 7-30.
2. *Cancer Facts & Figures*. American Cancer Society: Atlanta, 2017.
3. Coombs, C. C.; Tavakkoli, M.; Tallman, M. S., Acute promyelocytic leukemia: where did we start, where are we now, and the future. *Blood Cancer J* **2015**, 5, e304.
4. Forghieri, F.; Bigliardi, S.; Quadrelli, C.; Morselli, M.; Potenza, L.; Paolini, A.; Colaci, E.; Barozzi, P.; Zucchini, P.; Riva, G.; Vallerini, D.; Lagreca, I.; Marasca, R.; Narni, F.; Venditti, A.; Martelli, M. P.; Falini, B.; Lo Coco, F.; Amadori, S.; Luppi, M., All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature. *Clin Case Rep* **2016**, 4, (12), 1138-1146.
5. Glasow, A.; Barrett, A.; Petrie, K.; Gupta, R.; Boix-Chornet, M.; Zhou, D. C.; Grimwade, D.; Gallagher, R.; von Lindern, M.; Waxman, S.; Enver, T.; Hildebrandt, G.; Zelent, A., DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. *Blood* **2008**, 111, (4), 2374-7.
6. Schenk, T.; Chen, W. C.; Gollner, S.; Howell, L.; Jin, L.; Hebestreit, K.; Klein, H. U.; Popescu, A. C.; Burnett, A.; Mills, K.; Casero, R. A., Jr.; Marton, L.; Woster, P.; Minden, M. D.; Dugas, M.; Wang, J. C.; Dick, J. E.; Muller-Tidow, C.; Petrie, K.; Zelent, A., Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat Med* **2012**, 18, (4), 605-11.
7. Cancer Genome Atlas Research, N.; Ley, T. J.; Miller, C.; Ding, L.; Raphael, B. J.; Mungall, A. J.; Robertson, A.; Hoadley, K.; Triche, T. J., Jr.; Laird, P. W.; Baty, J. D.; Fulton, L. L.; Fulton, R.; Heath, S. E.; Kalicki-Veizer, J.; Kandoth, C.; Klco, J. M.; Koboldt, D. C.; Kanchi, K. L.; Kulkarni, S.; Lamprecht, T. L.; Larson, D. E.; Lin, L.; Lu, C.; McLellan, M. D.; McMichael, J. F.; Payton, J.; Schmidt, H.; Spencer, D. H.; Tomasson, M. H.; Wallis, J. W.; Wartman, L. D.; Watson, M. A.; Welch, J.; Wendl, M. C.; Ally, A.; Balasundaram, M.; Birol, I.; Butterfield, Y.;

- Chiu, R.; Chu, A.; Chuah, E.; Chun, H. J.; Corbett, R.; Dhalla, N.; Guin, R.; He, A.; Hirst, C.; Hirst, M.; Holt, R. A.; Jones, S.; Karsan, A.; Lee, D.; Li, H. I.; Marra, M. A.; Mayo, M.; Moore, R. A.; Mungall, K.; Parker, J.; Pleasance, E.; Plettner, P.; Schein, J.; Stoll, D.; Swanson, L.; Tam, A.; Thiessen, N.; Varhol, R.; Wye, N.; Zhao, Y.; Gabriel, S.; Getz, G.; Sougnez, C.; Zou, L.; Leiserson, M. D.; Vandin, F.; Wu, H. T.; Applebaum, F.; Baylin, S. B.; Akbani, R.; Broom, B. M.; Chen, K.; Motter, T. C.; Nguyen, K.; Weinstein, J. N.; Zhang, N.; Ferguson, M. L.; Adams, C.; Black, A.; Bowen, J.; Gastier-Foster, J.; Grossman, T.; Lichtenberg, T.; Wise, L.; Davidsen, T.; Demchok, J. A.; Shaw, K. R.; Sheth, M.; Sofia, H. J.; Yang, L.; Downing, J. R.; Eley, G., Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *The New England journal of medicine* **2013**, 368, (22), 2059-74.
8. Klcio, J. M.; Miller, C. A.; Griffith, M.; Petti, A.; Spencer, D. H.; Ketkar-Kulkarni, S.; Wartman, L. D.; Christopher, M.; Lamprecht, T. L.; Helton, N. M.; Duncavage, E. J.; Payton, J. E.; Baty, J.; Heath, S. E.; Griffith, O. L.; Shen, D.; Hundal, J.; Chang, G. S.; Fulton, R.; O'Laughlin, M.; Fronick, C.; Magrini, V.; Demeter, R. T.; Larson, D. E.; Kulkarni, S.; Ozenberger, B. A.; Welch, J. S.; Walter, M. J.; Graubert, T. A.; Westervelt, P.; Radich, J. P.; Link, D. C.; Mardis, E. R.; DiPersio, J. F.; Wilson, R. K.; Ley, T. J., Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. *Jama* **2015**, 314, (8), 811-22.
 9. Petrie, K.; Zelent, A.; Waxman, S., Differentiation therapy of acute myeloid leukemia: past, present and future. *Current opinion in hematology* **2009**, 16, (2), 84-91.
 10. Bacher, U.; Haferlach, T.; Schoch, C.; Kern, W.; Schnittger, S., Implications of NRAS mutations in AML: a study of 2502 patients. *Blood* **2006**, 107, (10), 3847-53.
 11. Scholl, C.; Gilliland, D. G.; Frohling, S., Deregulation of signaling pathways in acute myeloid leukemia. *Semin Oncol* **2008**, 35, (4), 336-45.
 12. Fernandez-Medarde, A.; Santos, E., The RasGrf family of mammalian guanine nucleotide exchange factors. *Biochim Biophys Acta* **2011**, 1815, (2), 170-88.
 13. Lenzen, C.; Cool, R. H.; Prinz, H.; Kuhlmann, J.; Wittinghofer, A., Kinetic analysis by fluorescence of the interaction between Ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25Mm. *Biochemistry* **1998**, 37, (20), 7420-30.

14. Simandi, Z.; Balint, B. L.; Poliska, S.; Ruhl, R.; Nagy, L., Activation of retinoic acid receptor signaling coordinates lineage commitment of spontaneously differentiating mouse embryonic stem cells in embryoid bodies. *FEBS letters* **2010**, 584, (14), 3123-30.
15. Shibata, H.; Yoda, Y.; Kato, R.; Ueda, T.; Kamiya, M.; Hiraiwa, N.; Yoshiki, A.; Plass, C.; Pearsall, R. S.; Held, W. A.; Muramatsu, M.; Sasaki, H.; Kusakabe, M.; Hayashizaki, Y., A methylation imprint mark in the mouse imprinted gene *Grfl/Cdc25Mm* locus shares a common feature with the *U2afbp-rs* gene: an association with a short tandem repeat and a hypermethylated region. *Genomics* **1998**, 49, (1), 30-7.
16. Gores, G. J.; Kaufmann, S. H., Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. *Genes Dev* **2012**, 26, (4), 305-11.
17. Takeishi, S.; Nakayama, K. I., Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. *Br J Cancer* **2014**, 111, (6), 1054-9.
18. Dobin, A.; Davis, C. A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T. R., STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **2013**, 29, (1), 15-21.
19. 19. Chen, X.; Schulz-Trieglaff, O.; Shaw, R.; Barnes, B.; Schlesinger, F.; Kallberg, M.; Cox, A. J.; Kruglyak, S.; Saunders, C. T., Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics* **2016**, 32, (8), 1220-2.